By Nonish / 27th July 2026
In the field of lung cancer, the development of treatments has developed fast with the advent of targeted therapy. One of these developments includes Mobocertinib, which targets a very rare but difficult to treat mutation in Non-Small Cell Lung Cancer (NSCLC). This treatment gives hope to those who have limited treatment choices.
Non-Small Cell Lung Cancer is the most prevalent lung cancer. Some patients suffer from a lung cancer that is due to a mutation of the EGFR (Epidermal Growth Factor Receptor) gene that leads to uncontrolled growth of cancer cells. In particular, Exon 20 insertions represent a rare but harder-to-treat form of this mutation since, unlike other types of EGFR mutations, they rarely respond to the traditional drugs used to inhibit EGFR activity. Thus, it is crucial to develop an alternative treatment aimed at these mutations.
Genetic testing before starting the treatment is a very important aspect since it allows determining if there is an EGFR Exon 20 insertion mutation in the patient. Otherwise, there will be a risk that patients get therapies that will not help with this specific cancer. Therefore, genetic testing is required to ensure:
The medicine is an orally administered, targeted therapy that has been designed for the treatment of NSCLC patients with EGFR Exon 20 insertion mutations. It is usually prescribed to patients who are undergoing advanced stages of cancer and who have not reacted positively to any other modes of therapy. In contrast to regular chemotherapy, which involves treatment to normal and abnormal cells equally, this pill is effective only against the genes that cause cancer.
The capsule acts through the targeting of abnormal EGFR proteins due to Exon 20 insertion mutations. Abnormal proteins act on cells and provide growth signals for tumors. By inhibiting these signals:
This treatment method makes the treatment more effective than conventional treatments.
However, like other cancer medications, this capsule may have side effects that may range from mild to moderate based on various factors such as the general health condition of the patients and how their body reacts to the treatment. Some common side effects are as follows:
Also, there are some more severe side effects that might occur, including those related to lungs and heart. Patient may visit the doctor when any of these symptoms persist or worsen.
The Mobocertinib is sold under various brand names depending upon availability and location. Some examples of brand names include:
Both have the same active component but differ in cost and availability.
Not all non-small-cell lung cancer patients can be treated using Mobocertinib. The medication is indicated only for patients who fulfill some set conditions. The patients who can be treated using this drug are:
The medicine is a new development in the treatment of NSCLC with EGFR Exon 20 Insertion Mutations. Since it targets the mutation, it becomes an innovative way to handle the condition and help the patients. Despite its inability to cure cancer completely, it helps in managing the progression of the disease and improving the quality of life of the patients. It can help as long as the patient is tested for the mutation and followed by a doctor.
1. Is this medicine suitable as a first-line therapy?
This medication is usually prescribed after other therapies fail, but sometimes it can be prescribed as a first line of treatment depending on the patient’s status and genetic mutation.
2. Is the medication a chemotherapeutic agent or targeted therapy?
It is considered to be targeted therapy because it targets only cancer cells that have EGFR Exon 20 insertion mutations unlike chemotherapy which attacks all rapidly dividing cells.
References